Navigation Links
Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
Date:2/15/2008

NEW YORK, Feb. 15 /PRNewswire/ -- Intra-Cellular Therapies, Inc. (ITI), announced the presentation of preclinical data on ITI-007, its first-in-class dual 5HT2A receptor antagonist/dopamine receptor phosphoprotein modulator (DPPM) for the treatment of schizophrenia, and ITI-002, ITI's family of compounds that inhibit a novel intracellular target for the treatment of cognitive dysfunction in schizophrenia. Data characterizing the pharmacological profile of these drug candidates were highlighted in an oral presentation given last week at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders. ITI-007 is currently in Phase I clinical trials for the treatment of schizophrenia.

"We believe the novel pharmacological properties of ITI-007 may provide new treatment alternatives with significant safety and patient compliance-related advantages over currently available therapies for the treatment of schizophrenia," said Sharon Mates, Ph.D., Chairman and Chief Executive Officer of Intra-Cellular Therapies. "In addition, we are developing ITI-002 to treat cognitive dysfunction in schizophrenia which remains an important quality of life issue for individuals with schizophrenia and is not addressed by current medications."

ITI-007 Study Results

In vitro, ITI-007 was shown to be a potent, sub-nanomolar, antagonist at 5HT2A receptors with a 60-fold higher affinity for 5HT2A receptors over D2 receptors. In vivo, ITI-007 produced an intracellular protein phosphorylation pattern consistent with the activity of a partial agonist at pre-synaptic D2 receptors. This pre-synaptic partial agonist activity preserves normal dopamine metabolism rather than causing a dramatic increase as seen with other antipsychotic therapies. Behaviorally, ITI-007 inhibited serotonin induced head twitches. Additionally, ITI-007 was shown to have an affinity for the serotonin reuptake site, an activity that potentially may be beneficial in treating affective disord
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
2. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
3. LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
4. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
5. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
6. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
7. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
8. Vital Therapies Announces Presentation of ELAD(R) Artificial Liver Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
9. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
10. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
11. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014 NxStage Medical, Inc. (NASDAQ: ... innovative dialysis products, announced today that the U.S. ... System One™ to perform hemodialysis overnight while the ... nocturnal hemodialysis. NxStage,s® System One is the first ... for this indication. Home nocturnal ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... of the "US Self-monitoring Blood Glucose Market" ... http://photos.prnewswire.com/prnh/20130307/600769 This market insight focuses on ... the United States . Reimbursement analysis ... Thorough product analyses for more than 73 SMBG meters ...
(Date:12/22/2014)... 2014 Research and Markets ( ... "Investment Analysis of the US Medical Device ... http://photos.prnewswire.com/prnh/20130307/600769 ... device sector identifies the key trends and rationale ... and mergers and acquisitions. The study ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3US Self-monitoring Blood Glucose Market 2Investment Analysis of the US Medical Device Sector 2
... 4 Phosphagenics,Limited (ASX: POH, AIM: PSG, OTCQX: ... will jointly commence a phase 2 human clinical,trial ... Phospha E(R),in the management of metabolic syndrome. ... double-blind phase 2,clinical trial, which will commence shortly. ...
... Ore., Oct. 3 Virogenomics, Inc. today,announced that ... grant from the,National Institute of Standards and Technology ... that tests for many different biological markers in,a ... could revolutionize research on and,the diagnosis of multifactorial ...
Cached Medicine Technology:Nestle Nutrition and Phosphagenics to Commence Phospha E(R) Phase 2 Clinical Trial 2Nestle Nutrition and Phosphagenics to Commence Phospha E(R) Phase 2 Clinical Trial 3Nestle Nutrition and Phosphagenics to Commence Phospha E(R) Phase 2 Clinical Trial 4Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors 2Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors 3Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors 4
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of wedding ... new selection of black one-shoulder cocktail dresses . In ... are available at discounted prices, up to 70% off. ... for three weeks only. You know, we have thousands of ... in our new items can visit our website for more ...
(Date:12/25/2014)... 2014 The short film “Color of Honor” ... honor of a true 9/11 hero, Welles Remy Crowther. It ... the 24 hours of Nuremberg International Short Film Festival and ... Actress, screenwriter and director Luciana Lagana plays the ... with her husband, Gregory Graham - Graham plays ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and the business ... company announces big discounts on its bamboo mats ... BambooFlooringChina.com is the world’s leader in bamboo flooring. According ... Jan. 20, 2015. , The bamboo mats are made ... thread. All the bamboo strips for the mats are ...
(Date:12/25/2014)... Miami, FL (PRWEB) December 25, 2014 When ... often find themselves in a frenzy to get rid of ... classroom. But families in Coral Gables now have the solution ... its second salon clinic location, Lice Troopers provides full spectrum ... in the Coral Gable area, including Sunset, Key Biscayne, Brickell, ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 (HealthDay ... receive effective, less expensive care from a clinic that functions ... of dedicated health care professionals, a new study shows. ... either hospitalization or a trip to the emergency room when ... the University of Texas in Houston versus usual care, according ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3
... In this News Digest:, Summary of a study being published ... finding that close relatives of women who carry mutations in ... genetic mutations -- do not have an increased risk of developing ... do not have such mutations. These results run counter to a ...
... , MONDAY, Oct. 31 (HealthDay News) -- People with ... disabled and less likely to return home than stroke patients ... looked at 702 people who had dementia at the time ... had a stroke. The stroke patients with pre-existing dementia ...
... - An unprecedented decade of economic demise and a population ... putting Michigan in a precarious spot: More aging residents needing ... Add in a steady decline in elderly support ratio ... and the situation becomes more dire. But with the help ...
... Men with prostate cancer are twice as likely to commit ... words may reduce this risk, reveals research at the Sahlgrenska ... a study at the University of Gothenburg,s Sahlgrenska Academy, researchers ... surgery for prostate cancer. The suicide rate in this group ...
... Oct. 31 (HealthDay News) --,The longer they live in the ... will develop health problems, a new study says. Researchers ... Examination Survey and discovered a dramatic increase in obesity, diabetes ... the United States for more than 20 years. Compared ...
... liberal in their advice to patients on alcohol consumption. ... while men who are heavy drinkers get to continue ... a thesis from the Sahlgrenska Academy at the University ... Gothenburg,s Sahlgrenska Academy have for the first time looked ...
Cached Medicine News:Health News:Study shows no increased risk of breast cancer for non-carriers in families with BRCA gene mutation 2Health News:Study shows no increased risk of breast cancer for non-carriers in families with BRCA gene mutation 3Health News:Dementia May Impede Stroke Recovery 2Health News:Michigan State University tackles health needs of an aging statewide population 2Health News:New findings could lower risk of suicide in men with prostate cancer 2Health News:Life in U.S. Not Always a Plus for Immigrants' Health 2Health News:Doctors' own alcohol consumption colors advice to patients 2
A highly precise stereotactic radiosurgery system for the treatment of intra-cranial lesions....
The Primus linear accelerator is a fully digital, technologically advanced radiation therapy treatment delivery system. It can be configured for delivery of routine, 3-D conformal or IMRT treatments....
... The cost-effective, proven and reliable ... rates for rapid patient treatment, fastest ... flatness - less than 500 milliseconds, ... highest beam stability, greatest number of ...
The Clinac 2100 C/D family of accelerators are reliable, easy-to-use, flexible and cost-effective systems....
Medicine Products: